HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.

Abstract
Experiments were performed to characterize the pharmacology of SCH 206272 [(R,R)-1'[5-[(3,5-dichlorobenzoyl)methylamino]-3-(3,4-dichlorophenyl)-4(Z)-(methoxyimino)pentyl]-N-methyl-2-oxo-[1,4'bipiperidine]-3-acetamide] as a potent and selective antagonist of tachykinin (NK) NK(1), NK(2), and NK(3) receptors. SCH 206272 inhibited binding at human tachykinin NK(1), NK(2), and NK(3) receptors (K(i) = 1.3, 0.4, and 0.3 nM, respectively) and antagonized [Ca(2+)](i) mobilization in Chinese hamster ovary (CHO) cells expressing the cloned human tachykinin NK(1), NK(2), or NK(3) receptors. SCH 206272 inhibited relaxation of the human pulmonary artery (pK(b) = 7.7 +/- 0.3) induced by the tachykinin NK(1) receptor agonist, [Met-O-Me] substance P and contraction of the human bronchus (pK(b = 8.2 +/- 0.3) induced by the tachykinin NK(2) receptor agonist, neurokinin A. In isolated guinea pig tissues, SCH 206272 inhibited substance P-induced enhancement of electrical field stimulated contractions of the vas deferens, (pK(b = 7.6 +/- 0.2), NKA-induced contraction of the bronchus (pK(b) = 7.7 +/- 0.2), and senktide-induced contraction of the ileum. In vivo, oral SCH 206272 (0.1-10 mg/kg, p.o.) inhibited substance P-induced airway microvascular leakage and neurokinin A-induced bronchospasm in the guinea pig. In a canine in vivo model, SCH 206272 (0.1-3 mg/kg, p.o.) inhibited NK(1) and NK(2) activities induced by exogenous substance P and neurokinin A. Furthermore, in guinea pig models involving endogenously released tachykinins, SCH 206272 inhibited hyperventilation-induced bronchospasm, capsaicin-induced cough, and airway microvascular leakage induced by nebulized hypertonic saline. These data demonstrate that SCH 206272 is a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. This compound may have beneficial effects in diseases thought to be mediated by tachykinins, such as cough, asthma, and chronic obstructive pulmonary disease.
AuthorsJohn C Anthes, Richard W Chapman, Christian Richard, Stephen Eckel, Michel Corboz, John A Hey, Xiomara Fernandez, Scott Greenfeder, Robbie McLeod, Susan Sehring, Charles Rizzo, Yvette Crawley, Neng-Yang Shih, John Piwinski, Greg Reichard, Pauline Ting, Nick Carruthers, Francis M Cuss, Motasim Billah, William Kreutner, Robert W Egan
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 450 Issue 2 Pg. 191-202 (Aug 23 2002) ISSN: 0014-2999 [Print] Netherlands
PMID12206858 (Publication Type: Comparative Study, Journal Article)
CopyrightCopyright 2002 Elsevier Science B.V.
Chemical References
  • Acetamides
  • Neurokinin-1 Receptor Antagonists
  • Piperidines
  • Receptors, Neurokinin-1
  • Receptors, Neurokinin-2
  • Receptors, Neurokinin-3
  • SCH 206272
  • Capsaicin
Topics
  • Acetamides (pharmacology)
  • Administration, Oral
  • Animals
  • Bronchoconstriction (drug effects, physiology)
  • CHO Cells
  • Capillary Permeability
  • Capsaicin (pharmacology)
  • Cough (chemically induced, drug therapy)
  • Cricetinae
  • Dogs
  • Dose-Response Relationship, Drug
  • Guinea Pigs
  • Humans
  • Ileum (drug effects, physiology)
  • In Vitro Techniques
  • Male
  • Muscle Contraction (drug effects)
  • Muscle, Smooth (drug effects, physiology)
  • Neurokinin-1 Receptor Antagonists
  • Piperidines (pharmacology)
  • Pulmonary Artery (drug effects, physiology)
  • Radioligand Assay
  • Receptors, Neurokinin-1 (metabolism)
  • Receptors, Neurokinin-2 (antagonists & inhibitors, metabolism)
  • Receptors, Neurokinin-3 (antagonists & inhibitors, metabolism)
  • Vas Deferens (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: